The Journal of Urology
Volume 179, Issue 4 , Pages 1587-1592, April 2008

PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome

  • Ina L. Deras

      Affiliations

    • Gen-Probe, Inc., San Diego, California
    • Equal study contribution.
    • Financial interest and/or other relationship with Gen-Probe.
  • ,
  • Sheila M.J. Aubin

      Affiliations

    • Gen-Probe, Inc., San Diego, California
    • Equal study contribution.
    • Financial interest and/or other relationship with Gen-Probe.
  • ,
  • Amy Blase

      Affiliations

    • Gen-Probe, Inc., San Diego, California
    • Financial interest and/or other relationship with Gen-Probe.
  • ,
  • John R. Day

      Affiliations

    • Gen-Probe, Inc., San Diego, California
    • Financial interest and/or other relationship with Gen-Probe.
  • ,
  • Seongjoon Koo

      Affiliations

    • Gen-Probe, Inc., San Diego, California
    • Financial interest and/or other relationship with Gen-Probe.
  • ,
  • Alan W. Partin

      Affiliations

    • The Johns Hopkins Medical Institutions, Baltimore, Maryland
    • Financial interest and/or other relationship with Gen-Probe.
  • ,
  • William J. Ellis

      Affiliations

    • University of Washington, Seattle, Washington
    • Financial interest and/or other relationship with Amgen, Medtronic and Onconome.
  • ,
  • Leonard S. Marks

      Affiliations

    • Urological Sciences Research Foundation, Los Angeles, California
    • Financial interest and/or other relationship with Allergan, American Medical Systems, Astellas, Bayer, Beckman Coulter, Diagnostic Ultrasound, GTX, GlaxoSmithKline, Gen-Probe, Light Science Oncology, Lilly ICOS, Merck, Novartis, Onconome, Pfizer, Sanofi, Solfay, Watson, National Institutes of Health Early Detection Research Network, Prostate Cancer Foundation CapCURE, Pardee Foundation and Seder Foundation.
  • ,
  • Yves Fradet

      Affiliations

    • Diagnocure Inc. and Université Laval, Quebec City, Quebec, Canada
    • Financial interest and/or other relationship with DiagnoCure, AstraZeneca and GlaxoSmithKline.
  • ,
  • Harry Rittenhouse

      Affiliations

    • Gen-Probe, Inc., San Diego, California
    • Financial interest and/or other relationship with Gen-Probe.
  • ,
  • Jack Groskopf

      Affiliations

    • Gen-Probe, Inc., San Diego, California
    • Financial interest and/or other relationship with Gen-Probe.
    • Corresponding Author InformationCorrespondence: Gen-Probe Inc., 10210 Genetic Center Dr., San Diego, California 92121 (telephone: 858-410-8850; FAX: 858-410-8302).

Received 3 July 2007 published online 22 February 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Study received approval from the institutional review board at each site.

 Supported by Early Detection Research Network Award CA86323, National Cancer Institute.

PII: S0022-5347(07)03077-7

doi:10.1016/j.juro.2007.11.038

The Journal of Urology
Volume 179, Issue 4 , Pages 1587-1592, April 2008